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EDITORIAL
Magnetic Resonance Imaging and Contralateral Prophylactic
Mastectomy: The ‘‘No Ma´s’’ Effect?
Todd M. Tuttle, MD
Division of Surgical Oncology, Department of Surgery, University of Minnesota, Minneapolis, MN
In a recent study using the Surveillance, Epidemiology,
and End Results (SEER) database, Tuttle et al. reported
that the use of contralateral prophylactic mastectomy
(CPM) among patients with unilateral invasive breast
cancer markedly increased from 1998 to 2003.1 The pri-
mary objective of the study in this issue of the Annals of
Surgical Oncology by Sorbero et al. was to determine if
preoperative magnetic resonance imaging (MRI) is asso-
ciated with higher CPM rates. The authors report that
patients who underwent breast MRI were more likely to
undergo CPM. Why would an MRI cause a breast cancer
patient to choose CPM? The proposed explanation goes
something like this: a patient with unilateral breast cancer
has an abnormal finding identified in the contralateral
breast by MRI; this finding leads to additional diagnostic
procedures (second-look ultrasound); these diagnostic
procedures lead to biopsy of the contralateral breast. Even
if the histological findings are not malignant, the anxiety
induced by MRI leads the patient to cry ‘‘no ma´s’’ and
she requests CPM to prevent similar future experiences.
Although this work by Sorbero et al. is an impor-
tant hypothesis-generating study, the actual relationship
between MRI and CPM is not so clear.
In most retrospective studies, the actual intent of a
particular diagnostic test or the choice of a specific treat-
ment is difficult to determine; for example, physicians may
be more likely to recommend breast MRI for a newly
diagnosed breast cancer patient with a known BRCA
mutation, infiltrating lobular histology, multicentric dis-
ease, or dense breast tissue on mammography. Physicians
may also be more likely to recommend CPM for patients
with these same characteristics; for example, lobular
histology was associated with a significantly increased
CPM rate [odds ratio = 2.18; 95% confidence interval
(CI) 2.01–2.34] in the SEER analysis. Unfortunately,
these specific characteristics were not available from the
database in the Sorbero study; thus, the authors could not
control for these potential confounding variables. More-
over, the authors did not report whether the MRI was a
staging procedure for a patient with an established breast
cancer or a screening procedure on a high-risk patient.
Finally, the results of the MRI were not reported in this
study. If the contralateral breast was normal on MRI, then
patients may be less likely to undergo CPM. On the other
hand, if the contralateral breast was abnormal on MRI and
additional diagnostic procedures were performed, then
patients may be more likely to undergo CPM.
Given these limitations, the authors evaluated the use of
MRI and CPM in two time periods: 1998 through 2000
(early) and 2003 through 2005 (late). When both time
periods were analyzed together, the authors found that MRI
was associated with a significantly higher CPM rate.
However, since MRI was rarely used for clinical staging of
breast cancer in the USA before 2001 (only 4.1% in this
series), the results from the early group of patients do not
reflect current breast cancer practice and are not relevant.
When the authors analyzed the late group, they found no
overall significant association between MRI and CPM
rates. However, a potential confounding factor is that
breast MRI may not be performed for patients who have
already decided to undergo CPM, thus diminishing a
potential association between MRI and CPM. When the
authors evaluated young patients (\51 years old) in the late
period, they found that MRI was significantly associated
with higher CPM rates. However, these younger patients
with unilateral breast cancer are more likely to have BRCA
mutations and to undergo both MRI and CPM.
Since the CPM trends that were observed in the SEER
database (1998 to 2003) preceded the widespread clinical
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use of breast MRI, the ‘‘no ma´s’’ effect is probably not the
main explanation for recent trends in breast cancer surgery
in the USA. Although abnormal breast MRI findings may
influence a patient’s decision to undergo CPM, other fac-
tors are probably more important. Increasing awareness of
genetic breast cancer and genetic testing probably con-
tribute to observed trends. Using an international BRCA
registry of patients with unilateral breast cancer and BRCA
mutation, Metcalfe et al. reported that 49% of patients in
the USA underwent CPM.2 Also, improvements in mas-
tectomy and reconstruction techniques may contribute to
increased CPM rates. Finally, surgeons may be partially
responsible for increased CPM rates in the USA. In a
review of the National Prophylactic Mastectomy Registry,
Montgomery et al. reported that the most commonly cited
reason for CPM, as cited by patients, was physician rec-
ommendation.3 For unclear reasons, surgeons may simply
recommend CPM more frequently. Future research should
concentrate on understanding the complex decision-making
processes between breast cancer patients and surgeons.
Ultimately, decision aids should be developed to assist
breast cancer patients.
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